• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » FDA approves implantable rechargeable spinal cord stimulation system from Abbott

FDA approves implantable rechargeable spinal cord stimulation system from Abbott

December 19, 2022 By Sean Whooley

Abbott marketing image of the Eterna spinal cord stimulation SCS system
The Eterna spinal cord stimulation (SCS) system [Image courtesy of Abbott]
Abbott (NYSE:ABT) announced today that the FDA approved its Eterna spinal cord stimulation (SCS) system.

Eterna is an implantable, rechargeable SCS system. It offers treatment for chronic pain. Abbott said in a news release that Eterna represents the smallest such SCS system on the market for that indication.

The system uses Abbott’s proprietary low-dose BurstDR stimulation. BurstDR mimics natural firing patterns around the brain to deliver pain relief. According to Abbott, this SCS waveform technology offers 23% more pain reduction compared to traditional waveform approaches.

Abbott said it developed Eterna based on extensive studies exploring the unmet needs of people living with chronic pain. The company discovered that people wanted a smaller implant for comfort and a reduced need to charge the device daily or weekly. As a result, it designed Eterna for recharging less than five times a year under normal use.

“Abbott’s low-dose BurstDR stimulation is clinically proven to reduce pain, improve people’s ability to perform everyday activities, and reduce emotional suffering associated with pain,” said Dr. Timothy Deer, president and CEO of the Spine and Nerve Centers of the Virginias in Charleston, West Virginia. “Until now, it wasn’t available on a rechargeable device that was this small, and that only needs to be charged a few times a year. This makes a big difference in comfort for many patients who now can have access to the best of both worlds – a small, best-in-class rechargeable device with superior stimulation therapy.”

More about the Eterna SCS system

Eterna pairs with Abbott’s new Xtend energy technology, the company said. This optimizes the charging experience, reducing it to as few as five recharges per year with a wireless charger.

Additionally, Eterna uses Abbott’s TotalScan MRI technology. TotalScan allows for full-body MRI scans for those who require accessibility to improved diagnostics and healthcare. Abbott noted that it designed Eterna as an upgradeable platform. This allows for adaptation to future innovations without replacing the implant.

The company offers iPhone integration for Eterna as well. Abbott’s patient-focused mobile app supports real-time battery life and charging status updates. Also, these can come on a personal or Abbott-provided Apple device.

“At Abbott, we deliver products and solutions with the goal of simplifying healthcare, improving clinical outcomes and providing people suffering from chronic pain with the best experience possible. As we progress on this commitment, Eterna is the next major leap forward,” said Pedro Malha, VP, neuromodulation, Abbott. “Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience – all key features when selecting the best overall system.”

Filed Under: Business/Financial News, Featured, Implants, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management Tagged With: Abbott

More recent news

  • FDA clears at-home dental dressing for non-surgical periodontal procedures
  • CVRx taps new CFO from Nyxoah
  • BD brings on new chief information and digital officer from Lenovo
  • Cooper Companies continues to see activist pressure to sell divisions, replace CEO
  • Cordis earns FDA nod for Selution SLR drug-eluting balloon

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy